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N--Alanyl-5-S-glutathionyl-3,4-dihydroxyphenylalanine(5-S-GAD), an antibacterial 
substance isolated from flesh fly, has been described as having multipotential biological 
activities toward various tissues.  However, there has been no report testing its action on 
neural cells.  In the present study, we investigate whether 5-S-GAD is neurotoxic or 
neuroprotective to the rat retina.  5-S-GAD at high doses (more than 200 pmol) induced 
apoptosis of retinal neurons 7 days after intraocular injection.  NMDA (50-100 nmol) 
induced loss of retinal ganglion cells (RGCs) and thinning of the inner retina 7 days after 
injection.  5-S-GAD at low doses (2-20 pmol) significantly attenuated the loss of RGCs and 
the thinning of inner retina induced by NMDA in a dose-dependent manner.  To understand 
the protective mechanism of 5-S-GAD, we investigated the influence of 5-S-GAD on the cell 
survival molecules, phospho-Akt and Bcl-2.  5-S-GAD (2-20 pmol) rapidly increased 
phospho-Akt expression 1-7 days and Bcl-2 expression 3-7 days after injection.  The cellular 
localization of this increase was both in bipolar cells and RGCs.  This neurosurvival effect of 
5-S-GAD was further tested using another toxic model of optic nerve injury.  5-S-GAD 
significantly blocked the apoptosis of RGCs 7 days after optic nerve crush.  These results 
show that 5-S-GAD (2-20 pmol) protects against the NMDA- and optic nerve crush-induced 
apoptosis of RGCs.  The neuroprotective action of 5-S-GAD in the retina might be mediated 
by the cell survival phopho-Akt/Bcl-2 system and offers a therapeutic option to rescue RGCs 
from various types of excitotoxic disease, such as glaucoma.
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N--Alanyl-5-S-glutathionyl-3,4-dihydroxyphenylalanine (5-S-GAD) was isolated 
from adult flesh fly as a defense protein produced in response to bacterial injection or body 
injury (Leem et al. 1996).  5-S-GAD was found to inhibit tyrosine phosphorylation of 
protein tyrosine kinases (Leem et al. 1998).  Among the protein tyrosine kinases are
receptors for growth factors, hormones and viral oncogene products such as v-Src or 
v-BCR-ABL.  This inhibition of tyrosine phosphorylation by 5-S-GAD leads to suppression 
of tumor cells.  5-S-GAD inhibits cell growth of some human tumor cells in vitro (Akiyama
et al. 2000) and in vivo angiogenesis of mouse S180 sarcoma cells (Nishikawa et al. 2006).  
The optimal concentration of 5-S-GAD for the inhibition of cell growth is relatively high, in 
the order of 10-100 M.  Although the biological activity of 5-S-GAD has been examined in 
a variety of cellular systems, its action on nervous system is totally unknown.  Therefore, in 
the present study, we tested how 5-S-GAD affects control retina and retina treated with 
excessive amounts of the glutamate receptor subtype agonist, (NMDA or optic nerve injury.  
Excitotoxicity induced by NMDA and delayed cell death by optic nerve injury are thought to 
be an experimental model for retinal ischemia and glaucoma (Lafuente et al. 2001).  The 
toxic effect of 5-S-GAD was examined in the control retina at doses of 2-2000 pmol.  The 
protective effect of 5-S-GAD was examined in the NMDA treated or optic nerve injured 
retina at doses of 2-20 pmol.  5-S-GAD at high doses (200-2000 pmol) was certainly
apoptotic to retinal cells, particularly retinal ganglion cells (RGCs), while 5-S-GAD at low 
doses (2-20 pmol) was oppositely protective against the NMDA- or optic nerve crush-induced 
cell damage to RGCs.  Such a hormesis-like action of 5-S-GAD is described here for the 
first time.  Furthermore, we sought the signaling cascade(s) operative in the





                                                                 < ----- Fig. 1
2.1. Induction of apoptosis in the rat retina by 5-S-GAD at high doses
When 5-S-GAD (2-2000 pmol) was injected into rat eye, no terminal transferase dUTP 
nick end labeling (TUNEL) -positive cells could be seen in the retina until 5 days after 
injection (data not shown).  However, a small number of TUNEL-positive RGCs appeared 7 
days after injection of 5-S-GAD (more than 200 pmol, Fig. 1D).  5-S-GAD (2000 pmol) 
induced apoptosis of almost all retinal neurons, including those in the outer nuclear, inner 
nuclear and ganglion cell layers (Fig. 1E).  No effect could be seen at low doses (2-20 pmol) 
of 5-S-GAD (Fig. 1B, 2 pmol; C, 20 pmol), like PBS treatment (Fig. 1A).
                                                                 < ----- Fig. 2
2.2. Prevention of NMDA-induced apoptosis in the retina by 5-S-GAD at low doses 
When NMDA (2-100 nmol) was injected into rat eye, concentrations of more than 20 
nmol significantly induced apoptosis of retinal cells in the inner nuclear layer and ganglion 
cell layer neurons within 72h after injection (Fig. 2B, 50 nmol; 2C, 100 nmol). However, to 
observe the maximum prevention effect of 5-S-GAD, we studied TUNEL assay at 7 days after 
injection.  Interestingly, the apoptosis of retinal neurons induced by 100 nmol NMDA 7 days 
after injection was significantly reduced by treatment with 2-20 pmol 5-S-GAD (Fig. 2D, 20 
pmol).  Such a dose of 5-S-GAD alone did not induce any apoptosis of retinal cells (see Fig. 
1C), as in the control (Fig. 2A). We qualitatively confirmed that most of apoptotic cells in the 
ganglion cell layer were RGCs using an immunohistochemial study with anti--tublinIII
(Koriyama unpublished data)
                                                                 < ----- Fig. 3




NMDA (100 nmol) induced RGC apoptosis 7 days after injection (Fig. 2).  We next 
examined actual loss of RGCs in the rat retina with HE staining.  RGCs were certainly lost 7 
days after NMDA injection (Fig. 3B) as compared with PBS treatment (Fig. 3A).  5-S-GAD 
(2-20 pmol) prevented the cell loss induced by NMDA (Fig. 3C).  Graphical quantification 
of cell loss induced by NMDA with or without 5-S-GAD is shown in Fig. 3D.  Thinning of 
the inner retina (marked with a vertical line in each figure) 7 days after NMDA treatment was 
additionally notable in comparison with controls (cf. Fig. 3A and 3B).  The thinning of the 
inner retina by NMDA was also prevented by prior injection of 2-20 pmol of 5-S-GAD (Fig. 
3C, E).  5-S-GAD (2-20 pmol) significantly blocked the loss of RGCs and the thinning of 
the inner retina induced by NMDA.  The thickness of the outer nuclear layer was not 
changed by NMDA treatment (Koriyama, unpublished data).
                                                             < ----- Figs 4 & 5
2.4. 5-S-GAD activates cell survival signals in the rat retina
We next examined the cell survival system responsible for the neuroprotective action of 
5-S-GAD (2-20 pmol), specifically by analyzing the levels of two representative cell survival 
molecules, phospho-Akt and Bcl-2, in the rat retina (Homma et al. 2007).  In control retina, 
weak immunoreactivity of phopho-Akt could be seen in the bipolar cells and ganglion cells 
(Fig. 4A).  5-S-GAD rapidly increased phospho-Akt expression in the retina 1 day after 
injection.  This increase in the level of phospho-Akt continued until at least 7 days after 
injection.  The cellular localization of this increase was in both ganglion cells and bipolar
cells, as detected with anti-phospho Akt antibody (Fig. 4B).  The phospho-Akt activity in 
bipolar cells was confirmed by double staining for protein kinase C (PKC) (Negishi et al.
1988).  The immunopositive reactivity of bipolar and ganglion cells induced by 5-S-GAD 
was unchanged under NMDA treatment (Fig. 4D).  No positive signals for phospho-Akt 
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were seen in the NMDA-treated retina (Fig. 4C).  We further examined Bcl-2 expression 
after 5-S-GAD injection.  In control retina, no significant immunoreactivity for Bcl-2 could 
be seen (Fig. 5A).  5-S-GAD at low doses (2-20 pmol) increased Bcl-2 expression in the rat 
retina 3 days after injection and this increase in the level of Bcl-2 continued until at least 7 
days after injection.  The cellular localization of this increase was also observed in both 
ganglion cells and bipolar cells with anti-Bcl-2 antibody (Fig. 5B).  The increase in the level 
of Bcl-2 in RGCs induced by 5-S-GAD was unchanged by NMDA treatment (Fig. 5D).  No 
positive staining for Bcl-2 was seen in the NMDA-treated retina (Fig. 5C).
                                                                < ----- Fig. 6                                                                
2.5. Quantitative measurement of phospho-Akt and Bcl-2 levels induced by 5-S-GAD            
Since 5-S-GAD rapidly increased the immunoreactiviity of phospho-Akt and Bcl-2 in 
the bipolar and ganglion cells 1-7 and 3-7 days after injection, respectively (Figs 4 & 5), we 
next measured the levels of these survival molecules by Western blotting analysis.  5-S-GAD 
alone increased phospho-Akt protein levels 2-fold in the retina 7 days after injection as 
compared with the control value (Fig. 6A).  Conversely, NMDA alone reduced the levels of 
phospho-Akt by 40% of control in the retina 7 days after injection.  The reduced levels of 
phospho-Akt induced by NMDA treatment was almost recovered by 5-S-GAD (Fig. 6A).  
5-S-GAD also increased Bcl-2 levels 1.6 fold in the retina 7 days after injection (Fig. 6B).  
NMDA alone decreased the levels of Bcl-2 in the retina 7 days after treatment by 40% of 
control value.  The reduced levels of Bcl-2 induced by NMDA treatment was recovered by 
5-S-GAD (Fig. 6B).
< ----- Fig. 7
2.6. 5-S-GAD does not affect glial activation induced by NMDA treatment      
To investigate the neuroprotective mechanism of 5-S-GAD against NMDA 
excitotoxicity, we studied the effect of 5-S-GAD on glial activation (Honjo et al. 2000).  
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NMDA induced glial activation, as revealed by positive immunohistochemical staining for
glial fibrillary acidic protein (GFAP) in Müller cells 7 days after injection (Fig. 7C), but no 
glial activation was seen in control retina (Fig. 7A).  No significant effect of 5-S-GAD (2-20 
pmol) on Müller cells could be seen with or without NMDA treatment (Fig. 7D and Fig. 7B).
                                                                 < ----- Fig. 8
2.7. 5-S-GAD prevents apoptosis of RGCs after optic nerve crush             
Optic nerve crush retrogradely induces cell death of RGCs in the rat retina 6-7 days 
after injury (Homma et al. 2007).  As shown in Fig. 8C, many RGCs in the rat retina became 
TUNEL positive 7 days after optic nerve injury (Fig. 8A).  5-S-GAD (20 pmol) clearly 
reduced the number of apoptotic RGCs 7 days after injury (Fig. 8D).  5-S-GAD (2-20 pmol) 
alone did not induce the appearance of any TUNEL-positive cells 7 days after injection (Fig. 
8B).  Figure 7E shows that 5-S-GAD significantly reduces the number of apoptotic RGCs




3.1. Hormesis-like action of 5-S-GAD for neuroprotection in the rat retina
5-S-GAD at high doses (200-2000 pmol) clearly induced apoptosis of retinal neurons,
including RGCs, 7 days after intraocular injection.  The toxic dose of 5-S-GAD delivered to 
the retina in this study is the same as the dose causing inhibition of cell growth in other 
cellular systems.  The inhibition of tumorigenesis of human melanoma and breast cancers 
was evoked by 100 M 5-S-GAD (Akiyama et al. 2000).  The inhibition of angiogenesis and 
monocyte-macrophage lineage cells was also evoked by 100 M 5-S-GAD (Nishikawa et al.
2006; Hijikata et al. 1999).  The doses of 5-S-GAD (2-2000 pmol) used in our study are
estimated to correspond to a concentration of roughly 0.01-10 M 5-S-GAD in the rat ocular 
fluid.  Sublethal doses of 5-S-GAD (2-20 pmol) rather induced neuroprotection of RGCs.  
The expression levels of the cell survival molecules phospho-Akt and Bcl-2 were enhanced 
1-3 or 3-5 days after injection, respectively.  The neuroprotective effect of 5-S-GAD was 
examined under the condition of NMDA excitotoxicity. It is currently accepted that most 
damaged cells (>70%) by NMDA are RGCs in ganglion cell layer (Siliprandi et al., 1992).
Furthermore, displaced amacrine cells in ganglion cell layer can easily excepted because their 
diameter is extremely smaller(<10 m) than that of RGCs. Dying of RGCs and thinning of
the inner retina were significantly blocked by 2-20 pmol of 5-S-GAD (Figs 2 and 3).  Thus, 
5-S-GAD at low doses (2-20 pmol) is neuroprotective toward RGCs, while 5-S-GAD at high 
doses (200-2000 pmol) stimulates apoptosis in the retina.  Such a hormesis-like action of 
5-S-GAD is first described in this study.  Although the signaling cascade downstream of 
5-S-GAD leading to the neuroprotection is unclear, this action could be explained as follows.  
Recently, Akiyama et al. (2007) reported that 5-S-GAD liberated o-semiquinone radical anion 
for inhibition of cell growth at high concentrations.  The apoptosis in the retina induced by 2 
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nmol 5-S-GAD might be caused by such a cytotoxic radical (H2O2).  Thus, we propose the 
following possibilities: (1) low doses (2-20 pmol) of 5-S-GAD liberate a small amount of 
radical, which in turn activates the cell survival molecule phospho-Akt; (2) 5-S-GAD (2-20 
pmol) activates a pathway involving phospho-Akt through the phosphatidylinositol-3
kinase/Akt system in rat RGCs, via either brain-derived neurotrophic factor or insulin-like
growth factor-I (Mansoar-Robay et al. 1994; Kermer et al. 2000; Homma et al. 2007); (3) 
5-S-GAD inhibits Src protein kinase leading to protection against NMDA excitotoxicity, as 
shown in hippocampal or striatal neurons after ischemic insult (Hou et al. 2007; Crossthwaite 
et al. 2004).  Through which possibilities 5-S-GAD is neuroprotective to the RGCs, is 
uncertain at present.  Anyhow, such hormesis like action of 5-S-GAD on the nervous cell 
system is enough considerable. 
3.2. Neuroprotective action of 5-S-GAD on glaucomatous conditions in the rat retina in 
vivo
Glaucoma is an optic nerve neuropathy caused by a complicated etiology including an
increase in intraocular pressure, ocular hypertension, optic disc ischemia and oxidative
stresses (Weinreb and Levin, 1999; Kuehn et al. 2005).  Progression of optic nerve 
degeneration finally results in cell death of RGCs and loss of vision.  The main therapeutic 
target for treating glaucoma is decreasing intraocular pressure (Bakalash et al. 2002).  An
anti-glaucoma drug with neuroprotective or neuroregenerative properties has been awaited for
a long time.  In this study, 5-S-GAD (2-20 pmol) clearly prevented RGCs from undergoing
cell death induced by NMDA and optic nerve injury.  These two models of RGCs damage 
are often used as glaucomatous conditions (Tezel and Wax, 1999).  The pathophysiology of 
NMDA exposure is simulated to be equivalent to ischemia, calcium overload, generation of 
super oxide or nitric oxide radicals (Lipton et al. 1994).  It is also well known that optic 
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nerve injury retrogradely induces apoptosis of RGCs 6-7 days after injury (Berkelaar et al.
1994).  Interestingly, expression of phospho-Akt was rapidly downregulated in rat RGCs 1 
day after optic nerve crush (Homma et al. 2007).  Since 5-S-GAD first activates 
phospho-Akt in the retina at 1-3 days (Fig. 4) followed by expression of Bcl-2 3-5 days after 
injection (Fig. 5), the activation of phospho-Akt plays a key role in the neuroprotection 
induced by 5-S-GAD.  The neuroprotective effect of 5-S-GAD is directly mediated through 
the phophos-Akt/Bcl-2 systems, but is not mediated by glial activation (Fig. 7).  It is well 
known that phospho-Akt increases synthesis of Bcl-2 protein via phosphorylation of cAMP 
response element binding protein (Pugazhenthi et al. 2000). Moreover, another cell survival 
factor, mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) was not activated by 
5-S-GAD (data not shown). Of course, further studies using other types of glaucoma model,
such as increasing intraocular pressure (Wang et al. 2005), are needed.  Taken together, these
data strongly indicate that this small peptide from flesh fly might become an epoch-making 
neuroprotective or neuroregenerative reagent against glaucomatous conditions.
In conclusion, 2-20 pmol (corresponding to 0.01-0.1 M in the ocular fluid) of 
5-S-GAD clearly protected the RGCs in rat retinas from cell death induced by exitotoxic 
NMDA or optic nerve injury in vivo.  The neuroprotective mechanism is thought to involve
activation of the cell survival phospho-Akt/Bcl-2 system.  Although the exact pathway 
leading to activation of this cell survival system is not yet clarified, these results strongly 
indicate that this novel action of 5-S-GAD might become a therapeutic option for rescuing




4.1.  Animals and surgery
Sprague-Dawley rats (body weights 250-300 g) were used throughout the study.  Rats 
were reared and handled according to NIH guidelines and the ARVO statement on the care 
and use of laboratory animals.  Rats were anesthetized by intraperitoneal injection of sodium 
pentobarbital (30-40 mg/kg body weight).  Various concentrations of NMDA or 5-S-GAD 
were injected intravitreally in a 5-l solution with a micro-syringe.  The optic nerve was 
crushed 1 mm away from the eyeball with forceps, as described elsewhere (Homma et al. 
2007).  Rats were reared in clear plastic cages and kept under a 12 h/12 h light-dark cycle at 
23˚C.
4.2. Morphological measurement of surviving RGCs in rats after NMDA and/or 
5-S-GAD treatment
Fixation and cryosection of retinal samples have been described elsewhere (Homma et 
al., 2007).  In brief, rat eyes were enucleated and fixed in 0.1 M phosphate buffer (pH 7.4)
containing 4% paraformaldehyde and 5% sucrose for 2 h at room temperature, followed by 
incubation in 20% sucrose overnight at 4˚C.  All eyes were then embedded into OCT 
compound in vinyl molds, and frozen in liquid nitrogen.  Retinal sections in central areas 
within 300-m were cut at 12-m thickness, and mounted onto silane-coated slides.  To 
evaluate surviving RGCs after treatment, we performed immunohistochemistry using 
anti--tublinIII antibody (TUJ1, R & D Systems, Minneapolis, USA) and HE staining.  The
number of surviving RGCs was performed by counting the cells with more than 10 m in 
diameter to avoid miscounting the displaced amacrine cells under microscopic observation of 
25 visual fields per retina (Sabel et al. 1995).  The thickness of the inner retina (outer 
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plexiform layer, inner nuclear layer, inner plexiform layer and ganglion cell layer) was 
calculated from transverse sections.  
4.3. TUNEL staining
After fixation and cryosection, retinal tissues were incubated in 0.1% Triton X-100 and 
0.1% sodium citrate for 15 min and rinsed in PBS.  DNA fragmentation of cells undergoing 
apoptosis was detected using an in situ cell death detection kit (Roche, Mannheim, Germany) 
containing terminal transferase and fluorescence dUTP.  The retinal tissue was incubated in 
this reaction mixture overnight at 37˚C, and rinsed twice in PBS. In each eye, the number of 
TUNEL-positive cells within 300-m of the optic disk was counted.   A positive control for 
the TUNEL staining was performed with DNase I treatment at 37˚C for 30 min.  A clear 
positive signal with DNA fragmentation could be observed in all retinal neurons (data not 
shown).
4.4. Immunohistochemistry
Immunohistochemical staining of cell survival molecules (phospho-Akt and Bcl-2) and 
retinal cell markers, including PKC for bipolar cells, GFAP for Müller cells, and -tublin III
for ganglion cells, has been described elsewhere (Koriyama et al. 2007).  The primary 
antibodies used were anti-mouse Bcl-2 (1:200), anti-mouse PKC (1:200) were purchased from 
Santa Cruz.  Anti-mouse phospho-Akt (1:500) and anti-mouse GFAP antibody (1:100) were 
purchased from Sigma-Aldrich, USA.  Following washing and blocking, tissue sections were 
incubated with primary antibodies overnight at 4˚C.  After washing, retinal sections were 
incubated with an Alexa Fluor 488 secondary antibody (Molecular Probe, Japan) for 
visualization at room temperature.
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4.5. Western blotting analysis of cell death and survival signals
Retinal extracts were prepared at 7 days after treatment. Retinas were immersed in 
Tris-HCl buffer (pH 7.4) containing a protease inhibitor cocktail (Sigma), and were then 
sonicated and centrifuged for 10 min at 1,000 g, as described previously (Koriyama et al., 
2003).  Following SDS-PAGE electrophoresis in 12.5% gel, proteins were transferred onto a 
nitrocellulose membrane (Amersham International, U.K.). The membrane was incubated in a 
blocking buffer (3% bovine serum albumin in PBS) for 1 h at room temperature, and probed 
with a primary antibody in blocking buffer overnight at 4˚C. The membrane was further 
washed, and probed with a secondary antibody in blocking buffer for 1 h at room temperature, 
and washed again.  The signal (56 kDa of p-Akt and 26 kDa band of Bcl-2 protein) was 
detected using 3, 3’-diaminobenzidine tetrahydrochloride. The same primary antibodies in 
immunohistochemical study were used. An appropriate anti-IgG antibody (Santa Cruz 
Biotechnology, CA) was used as secondary antibody (1:200-1,000). To comfirm the amount 
of protein on acrylamide gel, we performed staining for protein by rapid stain Coomasie 
brilliant blue kit (Nacalai Tesque, Kyoto). Each protein band was densitometrically analyzed 
by the NIH imaging software (NIH, Bethesda, MD, USA). All experiments were repeated at 
least 3 times.
4.6. Statistics
Values of surviving or apoptotic RGCs, retinal thicknesses and density of the band in 
Western blotting are indicated as means±S.E.M for 3 experiments.  Statistical significance 
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Fig. 1.  5-S-GAD induces apoptosis of retinal neurons at high doses.
5-S-GAD (2-20 pmol) did not induce any significant change in TUNEL staining in the rat 
retina 7 days after intravitreal injection (B, 2 pmol; C, 20 pmol).  5-S-GAD (200 pmol) 
induced apoptosis of some retinal ganglion cells (RGCs) in rat 7 days after injection (D) 
unlike the control (A).  5-S-GAD (2 nmol) induced apoptosis of almost all retinal neurons 
including outer nuclear, inner nuclear and ganglion cell layers 7 days after injection (E).  
Scale bar=50 m.
Fig. 2.  NMDA induces apoptosis of RGCs, which is prevented by 5-S-GAD at low doses.
NMDA (50 nmol) induced apoptosis of RGCs 7 days after intravitreal injection, as detected
by TUNEL staining (B), unlike the control (A).  NMDA (100 nmol) induced apoptosis of 
almost all RGCs and some inner nuclear neurons 7 days after injection (C).  With a
combination of 100 nmol of NMDA with 20 pmol of 5-S-GAD, the apoptosis of RGCs and 
some inner nuclear neurons induced by NMDA was greatly reduced (D).  Scale bar=50 m.
Fig. 3.  5-S-GAD at low doses protects against NMDA-induced loss of RGCs and thinning 
of the inner retina, as revealed by HE staining.
NMDA (100 nmol) induced loss of RGCs and thinning of the inner retina (marked with a 
vertical line) 7 days after intravitreal injection (B) as compared to the control (A).  Prior 
injection of 20 pmol of 5-S-GAD significantly reduced the loss of RGCs and the thinning of 
the inner retina induced by NMDA (C).  Scale bar=50 m.  Fig. 3D shows a graphical 
presentation of the loss of RGCs by induced NMDA (100 nmol) and its prevention by 
5-S-GAD (2-20 pmol).  *P<0.01 compared to the control.  +P<0.01 compared to NMDA 
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(100 nmol) treatment.  Fig. 3E shows a graphical presentation of the thinning of the inner 
retina by NMDA (100 nmol) and its protection by 5-S-GAD (2-20 pmol) 7 days after 
injection.  *P<0.01 compared to the control.  +P<0.01 compared to the NMDA (100 nmol)
treatment.
Fig. 4.  5-S-GAD induces phospho-Akt expression in the rat retina
5-S-GAD (20 pmol) induced strong immunoreactivity for phospho-Akt in bipolar and 
ganglion cells 1-7 days after injection (B, 2 days after injection); this was not seen in the
control retina, in which weak staining of bipolar and ganglion cells could be seen (A).  
NMDA (100 nmol) alone did not induce any immunoreactivity for phospho-Akt in the retina 
7 days after injection (C).  With a combination of NMDA and 5-S-GAD, strong
immunoreactivity for phospho-Akt could still be seen in the bipolar and ganglion cells 7 days 
after injection (D).  Scale bar=50 m.
Fig. 5.  5-S-GAD induces Bcl-2 expression in the rat retina.
5-S-GAD (20 pmol) induced strong immunoreactivity of Bcl-2 in RGCs and weak 
immunoreactivity in bipolar cells 3-7 days after injection (B, 5 days after injection), which 
was not seen in the control (A).  NMDA (100 nmol) alone did not induce any 
immunoreactivity of Bcl-2 in the retina 7 days after injection (C).  With a combination of 
NMDA with 5-S-GAD, positive immunoreactivity of Bcl-2 in the RGCs could still be seen 7 
days after injection (D).  Scale bar=50 m.
Fig. 6.  Quantitative analyses of phospho-Akt and Bcl-2 levels in the retina after 5-S-GAD 
injection.
The supernatants of retinal samples treated with 5-S-GAD and /or NMDA for 7 days were 
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subjected to Western blotting analysis.  (A) 5-S-GAD alone increased phospho-Akt levels 
2-fold in the retina 7 days after injection.  NMDA alone decreased phsopho-Akt levels by 
40% of control value.  5-S-GAD fully recovered the decrease by NMDA treatment.  
*P<0.05 vs. control.  +P<0.05 vs. the NMDA treatment (n=3).  (B) 5-S-GAD alone 
increased Bcl-2 levels 1.6 fold in the retina 7 days after injection.  NMDA alone decreased 
Bcl-2 levels by 40% of control value.  5-S-GAD fully recovered the decrease by NMDA 
treatment.  Electrophoretic bands for phsopho-Akt and Bcl-2 were shown in the upper side 
of each figure.
Fig. 7.  NMDA induces glial activation in the rat retina.
NMDA (100 nmol) induced strong immunoreactivity for GFAP in Müller cells 7 days after 
injection (C) unlike the control (A).  With a combination of NMDA and 5-S-GAD (20 pmol), 
no change in GFAP immunoreactivity in the Müller cells induced by NMDA could be seen in 
the retina 7 days after injection (D).  5-S-GAD alone did not evoke any GFAP 
immunoreactivity in the retina 7 days after injection (B).  Scale bar=50 m.
Fig. 8.  5-S-GAD protects RGCs against apoptosis after optic nerve crush.
Optic nerve crush induced specific apoptosis of RGCs 7 days after injury (C), unlike the 
control (A), as revealed by TUNEL staining.  5-S-GAD (20 pmol) significantly reduced the 
level of apoptosis of RGCs 7 days after treatment (D).  5-S-GAD alone did not induce 
apoptosis in the retina (B).  Scale bar=50 m.  Fig. 8E shows a graphical presentation of 
the number of apoptotic RGCs after optic nerve crush and its protection by 5-S-GAD.  
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